<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272478</url>
  </required_header>
  <id_info>
    <org_study_id>AML18</org_study_id>
    <nct_id>NCT02272478</nct_id>
  </id_info>
  <brief_title>Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations</brief_title>
  <acronym>AML18</acronym>
  <official_title>A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiff University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiff University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AML18 Trial will evaluate several relevant therapeutic questions in Acute Myeloid
      Leukaemia (AML), as defined by the WHO, and High Risk Myelodysplastic Syndrome. The trial is
      primarily designed for patients over 60 years considered fit for an intensive
      chemotherapeutic approach, but younger patients who may not be considered suitable for the
      concurrent NCRI AML Trial for younger patients may also enter. Patients for whom intensive
      chemotherapy is not thought suitable may enter the concurrent NCRI trial of less intensive
      therapy (LI1). Approximately 1600 patients will be recruited.

      At entry, a randomisation will compare a standard chemotherapy schedule DA
      (Daunorubicin/Ara-C) combined with 1 dose of Mylotarg (gemtuzumab ozogamicin, or GO) in
      course 1 against CPX-351. Patients who have known adverse risk cytogenetics (using Grimwade
      2010 classification favourable/intermediate/adverse) at diagnosis may enter a Phase 2
      evaluation of the combination of Vosaroxin plus Decitabine. Patients who achieve complete
      remission (CR) and who are MRD negative by flow cytometry after course one of DA will receive
      one further course of DA, with a randomisation to receive, either a course of DA or
      intermediate dose Cytarabine (IDAC) as a third course. Patients who are MRD negative by flow
      cytometry after course one of CPX-351 will receive up to 2 further course of CPX. Patients
      who fail to achieve a CR after course 1 of DA or who are MRD positive by flow cytometry or
      for whom MRD information is not available, are eligible to be randomised to compare DA with
      DA plus Cladribine (DAC) or FLAG-Ida for up to two courses of therapy. Patients who fail to
      achieve a CR after course 1 of CPX-351 or who are MRD positive by flow cytometry or for whom
      MRD information is not available are eligible to be randomised between a second course of
      standard dose CPX versus a repeat of the course 1 schedule. Patients receiving Vosaroxin and
      Decitabine are excluded from these post course 1 randomisations .

      Following the outcome of course 1, patients who received DA chemotherapy on course 1 will be
      randomised to receive further chemotherapy with the 2nd generation FLT3 inhibitor AC220.
      Patients randomised to AC220 will be allocated a maximum of 3 courses (short AC220) or 3
      courses plus maintenance for 1 year (long AC220). Patients receiving Vosaroxin and Decitabine
      are excluded from this randomisation.

      Patients will be eligible for a non-intensive allogeneic stem cell transplant if a suitable
      HLA matched donor is available.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AML18 is a trial primarily for older patients with AML and high risk Myelodysplastic Syndrome
      (MDS). It offers a randomised controlled Phase II/III trial which uses a factorial design for
      maximum efficiency to evaluate two induction options followed by treatment with small
      molecule beyond course 1, and dose intensification for patients without evidence of MRD
      negativity.

      There are five randomised comparisons within the trial:

        1. At diagnosis:

           For patients not known to have adverse risk cytogenetics DA chemotherapy plus a single
           dose of 3 mg/m2 of Mylotarg versus CPX-351. Patients with abnormal LFTs can enter the
           randomisation but receive DA alone or CPX-351.

        2. For patients who received DA chemotherapy but are not in CR or who are MRD +ve, or for
           whom MRD is not assessable.

           DA versus DAC versus FLAG-Ida

        3. All patients at second course who have received DA and have not received Vosaroxin and
           Decitabine induction AC220 versus no AC220 for a maximum of 3 cycles; then with or
           without maintenance for 1 year for patients allocated AC220

        4. For patients who are in CR or CRi and MRD -ve post course1 and have completed 2 courses
           of DA DA versus intermediate dose Cytarabine (IDAC)

        5. For patients who received CPX-351 chemotherapy but are not in CR or who are MRD +ve, or
           for whom MRD is not assessable CPX-351 100 units/m2 x 3 doses versus CPX-351 100
           units/m2 x 2 doses

      The trial will also assess:

        -  Non-intensive allogeneic stem cell transplant for patients with matched sibling or
           matched unrelated donors.

        -  The combination of Vosaroxin and Decitabine for those with known adverse risk
           cytogenetics at diagnosis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2014</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission (CR + CRi) achievement and reasons for failure (for induction questions)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of remission, relapse rates and deaths in first CR</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity, both haematological and non-haematological</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Supportive care requirements (and other aspects of health economics)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The relevance of the presence of a cytogenetic abnormality in the bone marrow of patients in morphological remission</measure>
    <time_frame>At study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relevance of molecular characteristics and response to treatment</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To store diagnostic tissue for future research in the AML Tissue Bank</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Acute Myeloid Leukaemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients not known adverse karyotype
Randomise between
Daunorubicin 60mg/m2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 10 inclusive (20 doses) Mylotarg (GO) 3mg/m2 on day 1 of DA chemotherapy
Versus
CPX-351 100 units/m2 on days 1, 3 and 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with known adverse karyotype
5 cycles of Vosaroxin and Decitabine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior to Course 2 - Patients receving DA plus GO in course 1 and MRD positive PC1
Randomise between
Daunorubicin 50mg/2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v.push on days 1 - 8 inclusive (16 doses)
Versus
Daunorubicin 50mg/m2 daily by i.v. infusion on days 1, 3 and 5 Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 8 inclusive Cladribine 5mg/m2 daily on days 1 - 5 inclusive
Versus Patients aged 60-69 Fludarabine 30mg/m2 daily on i.v. on days 2 - 6 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 6 inclusive
Patients aged 70+ Fludarabine 25mg/m2 daily i.v. on days 2 - 5 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 5 inclusive Idarubicin 5mg/m2 i.v. daily on days 3, 4 and 5 (3 doses)
And Randomisation to receive AC220 or not</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior to Course 2 - Patients that received DA plus GO in course 1 and MRD negative PC1
Randomisation to receive AC220 or not</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior to Course 2 for patients receiving CPX in course 1 and MRD positive PC1
Randomisation between
CPX-351 100 units/m2 on days 1, and 3 (CPX 200) versus CPX-351 100 units/m2 on days 1, 3 and 5 (CPX 300)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior to Course 3 - Patients that received DA plus GO in course 1 and MRD negative PC1
Randomise between Daunorubicin 50 mg/m2 daily by i.v. infusion on days 1 and 3 (2 doses) Cytosine Arabinoside 100 mg/m2 12-hourly by i.v. push on days 1 - 5 inclusive (10 doses)
versus
Intermediate dose Cytarabine (IDAC) schedule Cytosine Arabinoside 1g/m2 daily by 4 hour infusion on days 1- 5 inclusive (5 doses)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm A Mylotarg plus DA Versus CPX-351</intervention_name>
    <description>Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Mylotarg (GO)</other_name>
    <other_name>CPX-351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm B Vosaroxin and Decitabine</intervention_name>
    <description>If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Vosaroxin</other_name>
    <other_name>Decitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm D Small molecule or Not</intervention_name>
    <description>The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.</description>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>No AC220</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm C DA V FLAG-Ida V DAC</intervention_name>
    <description>If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.</description>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>DA</other_name>
    <other_name>FLAG-Ida</other_name>
    <other_name>DAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm E CPX-351 (200 V 300)</intervention_name>
    <description>If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).</description>
    <arm_group_label>Arm E</arm_group_label>
    <other_name>CPX-351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm F DA V IDAC</intervention_name>
    <description>Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.</description>
    <arm_group_label>Arm F</arm_group_label>
    <other_name>IDAC</other_name>
    <other_name>DA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients are eligible for the AML18 trial if:

          -  They have one of the forms of acute myeloid leukaemia, except Acute Promyelocytic
             Leukaemia as defined by the WHO Classification (Appendix A) this can be any type of de
             novo or secondary AML - or high risk Myelodysplastic Syndrome, defined as greater than
             10% marrow blasts (RAEB-2). (NB patients with prior MDS (&gt;10% blasts, RAEB2) have
             received azacitidine are not eligible for the trial, but patients with &lt;10% who have
             failed a hypomethylating agent and developed AML may enter the trial).

          -  Patients should normally be over the age of 60, but patients under this age are
             eligible if they are not considered eligible for the MRC AML19 trial please contact
             the trial team for further information.

          -  Patients entering the Vosaroxin/Decitabine arm must be over the age of 60 and have
             known adverse risk cytogenetics.

          -  They have given written informed consent.

          -  Serum creatinine ≤ 1.5 × ULN (upper limit of normal)

          -  Sexually mature males must agree to use an adequate and medically accepted method of
             contraception throughout the study if their sexual partners are women of child bearing
             potential (WOCBP). Men should be advised to not father a child while receiving trial
             treatment. Similarly women must agree to adequate contraceptive measures and avoid
             becoming pregnant while on protocol treatment. In both males and females these
             measures must be in place for at least 3 months following completion of Decitabine and
             at least 6 months after the last administration of Cladribine. The time period
             following treatment with Decitabine where it is safe to become pregnant is unknown. In
             the event of pregnancy at any point during the trial, the IMPs should be immediately
             stopped and the Trial Team should be contacted and pregnancy reporting procedures
             followed.

          -  ECOG Performance Status of 0-2

        Exclusion criteria

        Patients are not eligible for the AML18 trial if:

          -  They have previously received cytotoxic chemotherapy for AML [Hydroxycarbamide, or
             similar low-dose therapy, to control the white count prior to initiation of intensive
             therapy, is not an exclusion]

          -  They are in blast transformation of chronic myeloid leukaemia (CML)

          -  They have a concurrent active malignancy excluding basal cell carcinoma

          -  They are pregnant or lactating

          -  They have Acute Promyelocytic Leukaemia

          -  Known infection with human immunodeficiency virus (HIV)

          -  Patients with prior cumulative anthracycline exposure (from prior treatment of a non
             AML cancer) of greater than 300 mg/m2 daunorubicin (or equivalent).

          -  History of myocardial infarction (MI), unstable angina, cerebrovascular accident, or
             transient ischemic attack (CVA/TIA) within 3 months before entry

        Specific exclusion criteria for the Mylotarg Arm

          -  Pre-existing liver impairment with known cirrhosis

          -  Total bilirubin &gt; 1.5 x the upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) &gt; 2.5 x ULN

          -  Alanine aminotransferase (ALT) &gt; 2.5 x ULN

        Specific exclusion criteria for the Vosaroxin/Decitabine Entry

          -  Total bilirubin &gt; 1.5 x the upper limit of normal (ULN),

          -  Aspartate aminotransferase (AST) &gt; 2.5 x ULN

          -  Alanine aminotransferase (ALT) &gt; 2.5 x ULN

          -  Left ventricular ejection fraction (LVEF) &lt; 40% by multiple gated acquisition (MUGA)
             scan or echocardiogram (ECHO)]

        Specific exclusion criteria for CPX-351 treatment

          -  Hypersensitivity to cytarabine, daunorubicin or liposomal products

          -  History of Wilson's disease or other copper-metabolism disorder

        Specific exclusion criteria for Cladribine

        • Patient's serum creatinine must be within the local ULN to enter the randomisation.
        Patients for whom this is not the case can be randomised between the remaining options.

        In addition patients are not eligible for the AC220 randomisation if they have:

        Cardiovascular System Exclusion Criteria:

        Known serious cardiac illness or medical conditions, including but not limited to:

        I. Clinically unstable cardiac disease, including unstable atrial fibrillation, symptomatic
        bradycardia, unstable congestive heart failure, active myocardial ischemia, or indwelling
        temporary pacemaker II. Ventricular tachycardia or a supraventricular tachycardia that
        requires treatment with a Class Ia antiarrhythmic drug (e.g., quinidine, procainamide,
        disopyramide) or Class III antiarrhythmic drug (e.g., sotalol, amiodarone, dofetilide). Use
        of other antiarrhythmic drugs is permitted.

        III. Use of medications that have been linked to the occurrence of torsades de pointes (see
        Appendix for the list of such medications) IV. Second- or third-degree atrioventricular
        (AV) block unless treated with a permanent pacemaker V. Complete left bundle branch block
        (LBBB) VI. History of long QT Syndrome or a family member with this condition VII. Serum
        potassium, magnesium, and calcium levels not outside the laboratory's reference range VIII.
        QTc &gt;450 ms (average of triplicate ECG recordings); a consistent method of QTc calculation
        must be used for each patient's QTc measurements. QTcF (Fridericia's formula) is preferred.
        Please see the trial website for QTcF calculator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nigel Russell, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie King</last_name>
    <phone>02922510527</phone>
    <email>aml18@cardiff.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Severinsen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans B Ommen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev and Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Schöllkopf, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrik M Overgaard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duruta Weber, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Møller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominic Culligan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monklands Hospital</name>
      <address>
        <city>Airdrie</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Murphy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ysbyty Gwynedd Hospital</name>
      <address>
        <city>Bangor</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Seale, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital Bath</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Knechtli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary McMullin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartland Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manos Nikolousis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Craddock, DPhil</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Cahalin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ysbyty Glan Clwyd</name>
      <address>
        <city>Bodelwyddan</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Earnest Heartin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pilgrim Hospital</name>
      <address>
        <city>Boston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Kallmeyer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth General Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Chacko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Ackroyd, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology &amp; Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priyanka Mehta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Tawana, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UHW</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steve Knapper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Knapper, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Rye, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Countess of Chester Hospital</name>
      <address>
        <city>Chester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arvind Pillai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Richard's Hospital</name>
      <address>
        <city>Chichester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santosh Narat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Coventry and Warwickshire</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Harris, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derby Teaching Hospital</name>
      <address>
        <city>Derby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Amott, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Russell Hall</name>
      <address>
        <city>Dudley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupert Hipkins, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudhir Tauro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Johnson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Coppell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mhairi Copland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hairmyres Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Murphy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The New Victoria Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Loud, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Rye, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>Hamstead</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panagiotis Kottaridis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital</name>
      <address>
        <city>Inverness</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Duncan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahesh Prahladan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Crosshouse &amp; Ayr Hospital</name>
      <address>
        <city>Irvine</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Gordon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kettering General Hospital</name>
      <address>
        <city>Kettering</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Kwan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital</name>
      <address>
        <city>Kirkcaldy</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Campbell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Forth Valley Royal Hospital</name>
      <address>
        <city>Larbert</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugh Edwards, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Jame's University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Kelly, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Hodgson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lincoln County Hospital</name>
      <address>
        <city>Lincoln</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Kallmeyer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikram Singh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Patel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kavita Raj, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathew Smith, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Klammer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Taussig, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Khwaja, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maidstone District General Hospital</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evangelia Dimitriadou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleni Tholouli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Dennis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ray Dang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Milton Keynes</name>
      <address>
        <city>Milton Keynes</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moez Dungarwalla, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Jones, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northampton General Hospital</name>
      <address>
        <city>Northampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Parker, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norfolk &amp; Norwich University</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Collins, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nigel Russell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Oldham Hospital</name>
      <address>
        <city>Oldham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Osborne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paresh Vyas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Medd, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Corser, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Whiston Hospital &amp; St Helens</name>
      <address>
        <city>Prescot</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toby Nicholson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Greaves, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rowena Thomas-Dewing, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salisbury District Hospital</name>
      <address>
        <city>Salisbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Cullis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wexham Park Hospital</name>
      <address>
        <city>Slough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Offer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Richardon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stafford Hospital</name>
      <address>
        <city>Stafford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Revell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Royal Stoke</name>
      <address>
        <city>Stoke-on-Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srivinas Pillai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital</name>
      <address>
        <city>Sunderland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shikha Chattree, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Helier Hospital</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Stern, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Unmesh Monite, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torbay District General Hospital</name>
      <address>
        <city>Torquay</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Turner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryson Pottinger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hillingdon Hospital</name>
      <address>
        <city>Uxbridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Kaczmarski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pinderfields Hospital</name>
      <address>
        <city>Wakefield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Moreton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sandwell Hospital</name>
      <address>
        <city>West Bromwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farooq Wandroo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arrowe Park Hospital</name>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ranjit Dasgupta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wishaw General Hospital</name>
      <address>
        <city>Wishaw</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Murphy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Whitmill, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Worcestershire Royal Hospital</name>
      <address>
        <city>Worcester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Pemberton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Worthing Hospital</name>
      <address>
        <city>Worthing</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santosh Narat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Bond, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardiff University</investigator_affiliation>
    <investigator_full_name>Prof Nigel Russell</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

